Treating the Skin as a Sebaceous–Follicular System, Not a Series of Conditions

Blending Dermatology with Aesthetics – A Smart Proposition for a Thriving Medical Aesthetic Business

There is a persistent tendency within both dermatology and aesthetic medicine to categorise skin conditions according to how they present, rather than how they arise, which is understandable from a clinical workflow perspective but ultimately reductive when considered biologically. Acne, sebaceous hyperplasia, and hidradenitis suppurativa are typically positioned as separate entities, yet this compartmentalisation reflects surface-level observation rather than underlying mechanism.

When examined more closely, these conditions do not exist in isolation but sit along a continuum of dysfunction centred on the sebaceous gland and follicular unit, within which alterations in sebum composition, follicular architecture, microbial behaviour, and inflammatory signalling interact to produce very different clinical outcomes. The implication is not merely academic, because if the underlying system is shared, then treating each condition as a discrete entity becomes inherently incomplete and, in many cases, predictably inconsistent.

Acne is often the entry point into this system and is therefore the most extensively studied, with a well-established pathway involving increased sebum production, altered lipid composition, follicular obstruction, microbial proliferation, and an associated inflammatory cascade. Conventional treatments tend to target individual components of this pathway, with benzoyl peroxide reducing bacterial load at the expense of barrier integrity and antibiotics suppressing inflammation while introducing the well-recognised risks of resistance and dependency.

What is less frequently addressed is the functional environment within the follicle itself, which is where Tebiskin OSK Lotion and Spray — a Class III medical device formulation for comedogenic and inflammatory acne — take a fundamentally different position by focusing on normalisation rather than suppression. Through modulation of sebum composition, reduction of follicular obstruction, and interference with biofilm formation, they act upstream of visible inflammation, and this shift in intervention point is reflected clinically in a faster onset of action than benzoyl peroxide or antibiotics, achieved without the same degree of irritation and without contributing to antimicrobial resistance or MRSA risk.

When the same sebaceous–follicular framework is applied to sebaceous hyperplasia, the condition can be reconsidered beyond its usual classification as a structural abnormality requiring removal or destruction. While electrocoagulation and laser remain dominant approaches, they do not address the underlying functional state of the gland, and clinical experience with Tebiskin OSK Lotion suggests that this functional component is more significant than traditionally assumed. Lesions that would typically be regarded as static can reduce in prominence, in some cases becoming almost imperceptible within a relatively short timeframe, with durability of outcome that cannot easily be explained by surface-level mechanisms alone. This points towards modulation of sebaceous activity and restoration of a more physiologically balanced output, indicating that at least a proportion of sebaceous hyperplasia may be amenable to control rather than destruction.

At the more severe end of the spectrum, hidradenitis suppurativa represents a chronic and relapsing disorder of the follicular unit characterised by deep inflammation, nodules, and abscess formation, and remains one of the most challenging conditions to manage within dermatology. In this context, the relevance of the same active system extends beyond theoretical alignment and into published evidence, where an eight-week study using a topical spray formulation demonstrated improvement in both inflammatory and non-inflammatory lesions with good tolerability and no significant adverse effects. This does not suggest that such a formulation replaces systemic therapy in hidradenitis suppurativa, but it does demonstrate that a non-antibiotic topical system can exert measurable effects within a deep and complex follicular disease environment where biofilm formation, obstruction, and inflammation coexist.

Taken together, acne, sebaceous hyperplasia, and hidradenitis suppurativa can be understood not as separate diseases but as different expressions of a shared biological axis involving altered sebum composition, structural or functional follicular change, microbial imbalance, and inflammatory signalling. The differences lie in depth, severity, and clinical expression, rather than in fundamental origin.

Tebiskin OSK Lotion and Spray intervene at this shared level by influencing the environment in which these conditions develop rather than attempting to suppress their individual manifestations, and this systems-based approach offers a degree of coherence that is often lacking in fragmented treatment models. For clinics, this is not simply a matter of clinical refinement but a strategic shift, allowing practitioners to move from condition-specific interventions towards a more unified and biologically grounded framework that improves consistency of outcome, reduces relapse, and decreases reliance on antibiotics.

It also changes the nature of the consultation itself, as patients are no longer presented with isolated explanations and disconnected treatments but with a clear and coherent narrative that links their condition to an underlying system and provides a structured pathway to control it, improving understanding, adherence, and ultimately long-term outcomes, while strengthening the clinical credibility of the practitioner.

The significance of Tebiskin OSK therefore lies not only in its efficacy in acne, but in its position within the biological pathway where multiple conditions intersect, allowing it to influence the sebaceous gland, the follicular unit, and the microbial environment simultaneously. When intervention occurs at that level, rather than at the surface, the outcomes tend to be not only faster but fundamentally more durable.

SkinMed Positioning

At SkinMed, the direction of travel is clear: the future of aesthetic medicine lies not in increasingly sophisticated ways of managing visible symptoms in isolation, but in understanding and modifying the biological systems that give rise to them, and in doing so creating an approach that is both clinically credible and commercially scalable. By blending dermatology with aesthetics, clinics are able to move beyond cosmetic intervention and position themselves within a space that reflects how skin disease actually behaves, which is ultimately where both better outcomes and more sustainable businesses are built.